Australian Trade Mark Search

Australian Trade Mark Search is the Australian Government’s trade mark search system.

Additional fields:

Trade mark 2587929

IR number 1876367
Words FAYUVI
Image
Image description
Status protected: Registered/protected
Priority date 17 Oct 2024 (Convention)
Classes 5, 42, 44
Kind Word
Dates
Renewal due 14 Apr 2035
Registration advertised / published 22 Dec 2025
Entered on Register 22 Dec 2025
Acceptance advertised / published 13 Oct 2025
Acceptance 13 Oct 2025
IR notification 18 Sep 2025
Filing 14 Apr 2025
Registered from 14 Apr 2025

Owner Address for service
Ultragenyx Pharmaceutical Inc.
Davies Collison Cave Pty Ltd

IR Contact

Brian Focarino Cooley LLP


Goods & Services
Class 5: Pharmaceutical preparations for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders; gene therapy products for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders, namely, virus vector-based gene therapy preparations for intravenous delivery.
Class 42: Pharmaceutical, scientific, and medical research and development in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific research in the nature of conducting clinical trials for others in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical research and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of gene therapy, genetic, central nervous system, and lysosomal storage diseases and disorders; biomedical research in the field of gene therapy design and delivery; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery.
Class 44: Providing medical services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; medical consulting services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders, featuring inputting and collection of data and information on genetic, central nervous system, and lysosomal storage diseases and disorders for screening, diagnosis and treatment purposes via an online database; medical information services in the nature of providing information in the field of genetic, central nervous system, and lysosomal storage disease and disorder information based on collected patient data and information all for treatment and diagnostic purposes via a database; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders.

Convention details
Date 17 Oct 2024
Number 98806908
Country UNITED STATES OF AMERICA
Goods & Services
Class 05:
Pharmaceutical preparations for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders; gene therapy products for the treatment of genetic, central nervous system, and lysosomal storage diseases and disorders, namely, virus vector-based gene therapy preparations for intravenous delivery

Date 17 Oct 2024
Number 98806913
Country UNITED STATES OF AMERICA
Goods & Services
Class 42:
Pharmaceutical, scientific, and medical research and development in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific research in the nature of conducting clinical trials for others in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; scientific and medical research, namely, compiling and sharing of patient data for research purposes in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; providing medical research and scientific research information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; pharmaceutical, scientific, and medical research and development in the field of gene therapy manufacturing technology; biomedical and scientific research in the fields of gene therapy, genetic, central nervous system, and lysosomal storage diseases and disorders; biomedical research in the field of gene therapy design and delivery; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; scientific research in the nature of conducting clinical trials for others in the field of gene therapy design and delivery

Date 17 Oct 2024
Number 98806917
Country UNITED STATES OF AMERICA
Goods & Services
Class 44:
Providing medical services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; medical consulting services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of genetic, central nervous system, and lysosomal storage diseases and disorders, featuring inputting and collection of data and information on genetic, central nervous system, and lysosomal storage diseases and disorders for screening, diagnosis and treatment purposes; medical information services in the nature of providing a database in the field of genetic, central nervous system, and lysosomal storage disease and disorder information based on collected patient data and information all for treatment and diagnostic purposes; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic, central nervous system, and lysosomal storage diseases and disorders

Indexing constituents
Word Image